Ann: 2022 AGM & Key Dates, page-3

My belief is Freddie , now part of the board along with the rest of the board is working alongside regulatory authorities,FDA ,and EMA ,along with the upcoming IMPORTANT data is designing the phase 3 lung cancer design,I feel this awaited data results ,may well determine the FDA granting of fast track approval and very possible greater accreditation of breakthrough designation.Perhaps the release of this further proven up data is what is required for the regulators to make the final ph3 ruling and trial design.